US-based pharmaceutical company Eli Lilly has completed the $90m expansion of its biotechnology centre in San Diego, California.
The expanded facility will enable the company foster and support the discovery of medicines within its core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, in addition to the emerging area of pain.
The facility, along with the improved technology capabilities, is part of the company’s $850m US capital investment for this year.
Eli Lilly chairman, president and CEO David Ricks said: “This year we announced a commitment to invest $850m in our US operations based on our potential for growth and the company's long-standing investment in the US market.
“Today, as part of that commitment, we are pleased to say our research footprint in San Diego has been expanded.”
Eli Lilly’s San Diego centre comprises a new technologically advanced laboratory and an additional 180,000ft² of working space.
In addition to conducting preclinical and clinical immunology research, the extended space facilitates enhanced collaboration between the company experts in biotechnology, discovery chemistry and research technologies, while also supporting external collaborations.
Eli Lilly research laboratories president and science and technology executive vice-president Dr Jan Lundberg said: “Our expansion in San Diego is a prime example of investing in a research success story.
"Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in ten years.”